Form 4: Senseonics Holdings CMO Francine Kaufman Receives Significant Equity Grants

Senseonics Holdings, Inc. Chief Medical Officer and Director Francine Kaufman was granted 455,716 restricted stock units and 642,911 employee stock options on May 23, 2025.

Summary

• Francine Kaufman, Chief Medical Officer and Director of Senseonics Holdings, Inc. (SENS), reported an acquisition of equity securities.
• On May 23, 2025, Ms. Kaufman was granted 455,716 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, with a reported acquisition price of $0.
• These RSUs will vest in eight equal installments, with the first installment vesting on June 15, 2025, and the remaining seven installments vesting in six-month increments commencing on November 15, 2025, subject to continuous service.
• Following this transaction, Ms. Kaufman beneficially owns 2,599,910 shares of common stock directly.
• Additionally, on May 23, 2025, Ms. Kaufman was granted 642,911 employee stock options with an exercise price of $0.51.
• These options have an expiration date of May 22, 2035, and will vest in 48 equal monthly installments commencing on June 23, 2025, subject to continuous service.
• Following this transaction, Ms. Kaufman beneficially owns 642,911 derivative securities (employee stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 primarily reports a transaction, the granting of significant equity to a key executive like the CMO suggests confidence in her continued contribution and aligns her incentives with long-term company performance. There are no negative operational or financial disclosures, only the standard dilution associated with equity compensation.

Positives

• The significant equity grants (RSUs and stock options) align the Chief Medical Officer's interests with those of shareholders, potentially incentivizing long-term performance and retention.
• The grants represent a form of non-cash compensation, which can be beneficial for the company's cash flow management.

Negatives

• The issuance of new equity (upon RSU vesting and option exercise) could lead to a slight dilution for existing shareholders, although this is a common practice for executive compensation.

Future Outlook

The grants are structured with multi-year vesting schedules, indicating an expectation of continued service from the Chief Medical Officer and a long-term incentive for her contribution to the company's future performance.

Management Comments

• The filing indicates that the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity compensation grant to a key executive. Such grants are common practice across industries, particularly in technology and medical device sectors like Senseonics, to attract, retain, and incentivize top talent.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting and exercise of the granted securities, but also benefit from incentivized executive performance and retention.
• Employees: The grants to a key executive may signal stability and a commitment to long-term incentives within the company.

Next Steps

• The Restricted Stock Units (RSUs) will begin vesting on June 15, 2025, with subsequent installments every six months.
• The employee stock options will begin vesting in 48 equal monthly installments commencing on June 23, 2025.

Key Dates

Keywords

Senseonics Holdings, SENS, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Chief Medical Officer, Francine Kaufman